25+ years as Clinical and Regulatory Strategist

Former Licencing and Clinical Trials Assessor at MHRA (UK Healthcare Regulator)

25+ years of experience in FDA & EMA Reglatory Affairs

Former EU Medical DIrector for Neuroscience at Novartis

20+ years in engineering and biotechnology industries

Previously CEO of Grand Peak Capital Corp., a publicly listed venture fund; Current CFO Stock Trend Capital.AI Fund

15 years as the Director of Listings for the TSX Venture Exchange.

Rob also has extensive knowledge in, policies, regulatory compliance and risk mitigation.

10+ years experience in medicinal mushrooms and botanical extraction, with contributions to neurodegenerative clinical trials and expertise in GLP systems

Co-founded Marygold Laboratories and ARextracts for botanical testing

An expert Toxicologist and Pharmacologist, having authored more than 170 published peer reviewed 2021

He was included in the world’s top 2% of Scientists, which ranks the most highly cited scientists globally.

Senior Editor Psychoactives of MDPI Medical Journal

Barney Neal is a digital health and biotech operator at the intersection of psychedelics, AI, and clinical delivery. As CTO and co-founder of the Psychedelic Medicine Association, he helped build clinician-focused infrastructure to educate, onboard, and connect providers to psychedelic-assisted therapies—experience directly applicable to compliant triage, care pathways, and outcomes reporting in digital clinicc.

He also quarterbacked the creation of Longr as co-founder/CTO, translating AI and product rigor into scalable health platforms—skills he brings to Albert Labs’ digital mental health clinic and Neuropath AI for intelligent intake, RWE-grade outcomes, and investor-transparent dashboards. Previously, Barney served in leadership at Albert Labs, supporting its capital-markets journey and RWE strategy, aligning clinical and commercialization goal

Advisor, Health Benefits Strategy & Payer Commercialization

• Serves as Senior Vice President of Individual Products at Alberta Blue Cross and Executive Committee member, leading strategic initiatives that drove revenue growth and market share expansion across Canada’s second-largest health benefits provider.

• Brings nearly 30 years of progressive healthcare navigation expertise, architecting benefit plan optimization frameworks and trusted partnership ecosystems across the Canadian health benefits sector with deep stakeholder engagement experience.

• Spearheaded cross-functional teams to align operational strategies with corporate growth objectives, delivering measurable improvements in customer acquisition, operational efficiency, and organizational accountability.

• Founded performance-based evaluation systems and recruited high-performing commercial teams, scaling new business development capabilities while maintaining disciplined budget forecasting and P&L alignment.

• Holds LLQP certification (Life & Accident & Sickness); completed Executive Development in Sales & Strategy at Queen’s University; chaired employee-led Hearts of Blue charity committee (1999–2022).

• Directly strengthens Albert Labs’ investment case by de-risking payer adoption pathways for NeuroPath AI and NeuroNature anxiety treatment platforms, accelerating reimbursement readiness and compressing time-to-revenue through validated coverage frameworks that demonstrate quantifiable cost savings to Canadian health benefit providers and provincial authorities.

Anton Millar CFA, CA(SA)

Advisor, Private Investor

• Led TSC Capital’s principal investments to scale healthcare assets, including a significant stake in Cure Day Hospitals Holdings (14 hospitals, 46 theatres), delivering multi‑year value creation and governance impact as Main Board Director and Audit & Risk Committee member.
• Previously spent 20 years in global investment banking, structuring cross‑border acquisition, asset‑based, equity‑linked, and debt capital markets financings, contributing to multi‑hundred‑million transactions and BEE mandates.
• Brings 25+ years of P&L-grounded leadership across financial services, healthcare, and renewables; served on 200+ boards with continental and international scope.
• Co‑founded and chairs Fairview Partners; pioneered venture investments in novel pharma, medical devices, and FoodTech with disciplined risk governance.
• Credentials: CFA; Chartered Accountant (SA, Deloitte articles); B.Bus.Sci (Hons) UCT; H.Dip Acc Wits; executive programs at INSEAD and Singularity—combining capital markets rigor with healthcare commercialization expertise.

Ajit Johal BSP RPh BCPP CTH

Chief Education Officer & Strategic Advisor, Psychedelic Medicine

• Clinical Instructor at UBC Faculty of Pharmaceutical Sciences since 2015, pioneering Canada’s first Travel Medicine elective (PHM 450B) and serving as Module Lead for Neurology & Psychiatry in the Flexible Doctor of Pharmacy Program—training 264+ students in travel health and 78+ annually in psychiatric pharmacy specializations
• Board-Certified Psychiatric Pharmacist (BCPP) with 13+ years clinical expertise in psychotropic medication management, PTSD protocols, and treatment-resistant depression—leading the multi-center EPICA trial advancing clozapine therapy optimization for community mental health patients
• Delivered $1M+ in national pharmaceutical education as Contributing Academic Author for MD Briefcase, Ensemble IQ, and Pear Health, creating evidence-based continuing education reaching thousands of Canadian pharmacists on immunizations and psychiatric care
• Presented at 40+ international conferences including Moderna’s Barcelona Expert Forum and Pfizer’s Amsterdam MOVE Global Meeting, representing Canada’s community pharmacy perspective on vaccine education and mental health innovation
• Founded TravelRx Education and Immunize.io Health Association while serving on BC Pharmacy Association Board of Directors (2020-2022)

Barney Neal is a digital health and biotech operator at the intersection of psychedelics, AI, and clinical delivery. As CTO and co-founder of the Psychedelic Medicine Association, he helped build clinician-focused infrastructure to educate, onboard, and connect providers to psychedelic-assisted therapies—experience directly applicable to compliant triage, care pathways, and outcomes reporting in digital clinicc.

He also quarterbacked the creation of Longr as co-founder/CTO, translating AI and product rigor into scalable health platforms—skills he brings to Albert Labs’ digital mental health clinic and Neuropath AI for intelligent intake, RWE-grade outcomes, and investor-transparent dashboards. Previously, Barney served in leadership at Albert Labs, supporting its capital-markets journey and RWE strategy, aligning clinical and commercialization goal

Senior Lecturer of Clinical Psychology at University of Manchester

Former Compass Pathways Training Programme Lead

Harold Davidson brings over 30 years of executive leadership in technology, specializing in taking innovative solutions from concept to market. As a co-inventor of AI modules for healthcare workflows his expertise directly aligns with Albert Labs’ mission to develop advanced AI solutions for mental health. He has a proven track record of architecting complex tech systems, securing patents, and successfully commercializing ventures, including board roles of public companies.

His strategic vision and hands-on experience in enterprise sales and government partnerships in Canada are invaluable for Neuropath AI’s market entry and adoption. Harold’s role as a Director and technical leader will be pivotal in guiding the development of Neuropath AI’s complete digital mental health clinic MVP, ensuring both technical excellence and commercial viability for investors.

BIO

Dr. JJ Sidhu serves as Medical Director of Psychiatry at Vancouver General Hospital, bringing frontline expertise in mental health system challenges and care delivery optimization. With extensive experience in psychiatric assessment, treatment protocols, and clinical workflow design, Dr. Sidhu advises Neuropath AI on developing clinically validated, AI-enabled mental health solutions for PTSD and anxiety disorders.

His leadership in one of Canada’s largest psychiatric programs provides critical insights into real-world adoption barriers, regulatory pathways, and integration requirements for digital mental health tools. Dr. Sidhu ensures Neuropath AI’s innovations meet rigorous clinical standards while addressing practical needs of therapists and healthcare systems.

BIO

Ravi Pannu, BBA

Advisor

• Successfully guided multiple companies through public listings and capital markets navigation, leveraging expertise in venture capital, asset management, and equities to deliver sustainable market performance
• Led ARZone Modulars Inc. as CEO, driving strategic growth across mining, metals, finance, and real estate development sectors with 25+ years of executive leadership experience
• Directed complex real estate investment and development projects across British Columbia, creating long-term value and contributing to regional economic expansion
• Proven track record in strategic financial planning, investor relations, and high-value opportunity identification across diverse industries including mining & metals and commercial real estate
• Holds Bachelor of Business Administration from Simon Fraser University; recognized for entrepreneurial vision and expertise in structuring strategic investments and negotiating complex multi-stakeholder transactions

Jagdeep Gill LLB (Hons), LLM (IP)
Managing Director, Neuro Nature LDA | Director, Albert Labs International Corp.

• Founded and scaled Bishop Sixth Sense, commercializing proprietary IP infringement detection software that orchestrated international investigations with international law enforcement agencies and the world customs organization, protecting billions in corporate assets across EMEA while serving as Chairman of the Imaging Consumables Coalition of EMEA (ICCE) (1997–2009).

• Led transformational GDPR and AML compliance frameworks for multinational banking institutions at Ernst & Young (2018–2020), architecting enterprise-wide cybersecurity and regulatory risk mitigation solutions across international financial networks.

• Brings 30+ years converting complex regulatory challenges into competitive advantages—from anti-counterfeiting ecosystems to cutting-edge data protection infrastructures—with proven expertise in patent strategy, novel foods regulatory pathways (GRAS, EU Novel Foods, Belgium Dietary Supplements), and EU funding applications.

• Credentials: LLM Intellectual Property Laws (Queen Mary); LLB (Hons) Law (London School of Economics); Advanced Certificate in Anti-Money Laundering (Merit, ICA).

• Directly strengthens Albert Labs’ investment case by architecting HIPAA-compliant data governance frameworks for AI-driven mental health platforms, de-risking US and EU regulatory pathways for natural anxiolytics, and building robust patent portfolios—enhancing institutional partnerability and investor confidence in commercial readiness.

15+ years of management experience leading a team of medical writers and scientific communications specialists in regulatory, safety, market access, and health economics across a range of therapeutic areas

Dr. Hyder A. Khoja, Ph.D., is a biotech innovator with 22+ years spanning drug discovery, nutraceuticals, and psychedelics. A co-founder of InMed Pharmaceuticals and former CSO across multiple life science ventures, he has led extraction, standardization, and scale-up of plant/fungal bioactives, developed IP, and navigated regulatory pathways with EFSA/FDA/Health Canada alignment. He has advanced cannabinoid, kava, catuaba, and lion’s mane programs from lab to commercialization.

At Neuronature LDA, Dr. Khoja will drive the Anxiety Project from technical specs to pilot production—optimizing formulations, delivery systems, stability, toxicology, and preclinical efficacy—while integrating AI-driven analytics for QC and process design. His partnerships and fundraising track record accelerate translation to market.

Azeem Shan, BSc (Hons), MRPharmS, is an experienced UK/ EU Qualified Person (QP) based in the UK. A pharmacist by training, he has over a decade of experience in the manufacturing, packaging, testing, and distribution of human and veterinary medicines. Azeem has first-hand experience setting up quality management systems, facility builds & expansions, performing audits of UK/EU GDP & GMP facilities, and providing support with remediation issues relating to regulatory compliance. His expertise covers UK/EU GMP requirements, including successful Medicines and Healthcare Products Regulatory Agency (MHRA) and Veterinary Medicines Directorate (VMD) inspections, along with site support for a variety of other international regulatory agencies.

Diogo Cortinhal MSc

Advisor, EU Funding and Market Development

• Led 200+ successful EU/Portugal 2020 funding submissions, unlocking multimillion-euro innovation capital; builds compliant reimbursement systems with audit-ready quarterly reporting.
• Former Head of Corporate at FNWAY (7+ years): directed grant strategy, feasibility studies, and institutional relations; now CEO of MShare (recognized TOP 5% SMEs in Portugal, 2023–2024).
• 10+ years in European incentives, internationalization, and market entry—specializing in digital health, R&D tax credits (SIFIDE), and Portugal 2030 programs.
• Pioneered cross-sector consortia (universities, insurers, health providers) to accelerate pilots in workplace anxiety and AI-enabled mental health.
• Expert in stakeholder engagement (banks, CCDR, municipal agencies), commercialization roadmaps, and partner sourcing; delivers investor-grade applications, contact maps, and pilot MoUs that de-risk scale-up. Education: BSc Management (University of Aveiro); MSc in Management, Marketing & International Relations.

Numair is a UK registered pharmacist and EU/UK QPPV. He has over a decade of experience in the production, quality assurance and pharmacovigilance of products. Numair has managed multiple disciplinary teams for companies holding over 30 UK Marketing Authorisations. He has worked extensively with the NHS in technical services, providing quality assurance and production expertise for Aseptic production units working under MS License. Numair has worked on manufacturing clinical trial products for the treatment of COVID-19 and Brain Tumours. He also formed part of the team that produced the first commercial batch in the UK for Gene Therapy product, Zolgensma: a life-saving drug worth £1.8 million that can enable mobility in babies and young children suffering from a rare genetic condition.